Shares of Horizon Pharma PLC (NASDAQ:HZNP) have earned an average recommendation of “Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $19.18.
Several research analysts recently weighed in on HZNP shares. Zacks Investment Research lowered shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. BidaskClub lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Sunday, October 15th. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $12.00 to $18.00 in a research note on Friday, January 12th. Finally, Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Friday, December 1st.
A number of hedge funds have recently made changes to their positions in the business. Advantage Investment Management LLC raised its holdings in shares of Horizon Pharma by 164.8% in the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,900 shares during the last quarter. Family Management Corp acquired a new stake in shares of Horizon Pharma in the second quarter valued at approximately $131,000. Brown Advisory Inc. acquired a new stake in shares of Horizon Pharma in the third quarter valued at approximately $145,000. Prudential Financial Inc. raised its holdings in shares of Horizon Pharma by 5.0% in the second quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 830 shares during the last quarter. Finally, Fox Run Management L.L.C. raised its holdings in shares of Horizon Pharma by 21.5% in the fourth quarter. Fox Run Management L.L.C. now owns 19,200 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 3,400 shares during the last quarter. Hedge funds and other institutional investors own 86.58% of the company’s stock.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The business had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. During the same quarter last year, the firm earned $0.70 EPS. Horizon Pharma’s quarterly revenue was up 30.1% compared to the same quarter last year. equities research analysts expect that Horizon Pharma will post 0.72 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3145806/horizon-pharma-plc-hznp-receives-average-recommendation-of-buy-from-analysts.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.